Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Deglutition | 6 | 2021 | 221 | 1.040 |
Why?
|
Deglutition Disorders | 5 | 2021 | 297 | 0.640 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2021 | 629 | 0.620 |
Why?
|
Head and Neck Neoplasms | 6 | 2021 | 561 | 0.610 |
Why?
|
Breast Neoplasms | 8 | 2019 | 1536 | 0.590 |
Why?
|
Respiratory Mechanics | 1 | 2016 | 33 | 0.550 |
Why?
|
Respiration | 1 | 2016 | 91 | 0.530 |
Why?
|
Mouth Neoplasms | 3 | 2021 | 206 | 0.450 |
Why?
|
Caregivers | 3 | 2019 | 365 | 0.360 |
Why?
|
Oncogenes | 2 | 2022 | 71 | 0.360 |
Why?
|
Barium | 3 | 2020 | 52 | 0.360 |
Why?
|
Survivors | 4 | 2015 | 256 | 0.340 |
Why?
|
Skin Neoplasms | 3 | 2019 | 375 | 0.340 |
Why?
|
Aged | 25 | 2021 | 14862 | 0.330 |
Why?
|
Neoplasms | 4 | 2022 | 1667 | 0.330 |
Why?
|
Pharynx | 3 | 2020 | 89 | 0.330 |
Why?
|
Neuropilin-2 | 2 | 2020 | 19 | 0.320 |
Why?
|
Cancer Survivors | 3 | 2019 | 146 | 0.320 |
Why?
|
Female | 37 | 2021 | 38074 | 0.310 |
Why?
|
Middle Aged | 27 | 2021 | 21147 | 0.310 |
Why?
|
Humans | 51 | 2022 | 68618 | 0.300 |
Why?
|
Liposomes | 2 | 2018 | 107 | 0.290 |
Why?
|
Protein Kinase Inhibitors | 2 | 2020 | 331 | 0.290 |
Why?
|
Fever | 2 | 2018 | 96 | 0.280 |
Why?
|
Lung Neoplasms | 4 | 2020 | 1173 | 0.280 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 468 | 0.280 |
Why?
|
Patient Compliance | 3 | 2019 | 402 | 0.280 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2021 | 756 | 0.270 |
Why?
|
Lymph Nodes | 3 | 2012 | 258 | 0.270 |
Why?
|
Contrast Media | 3 | 2019 | 595 | 0.270 |
Why?
|
Population Surveillance | 2 | 2019 | 285 | 0.260 |
Why?
|
Needs Assessment | 2 | 2019 | 186 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 300 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2021 | 446 | 0.250 |
Why?
|
Male | 28 | 2021 | 37321 | 0.250 |
Why?
|
Cell Line, Tumor | 9 | 2022 | 1851 | 0.240 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 454 | 0.240 |
Why?
|
Fluoroscopy | 3 | 2021 | 152 | 0.230 |
Why?
|
Mammography | 2 | 2019 | 310 | 0.230 |
Why?
|
Quality of Life | 5 | 2019 | 1515 | 0.230 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2020 | 332 | 0.220 |
Why?
|
Adult | 19 | 2020 | 21403 | 0.220 |
Why?
|
Aged, 80 and over | 12 | 2020 | 4848 | 0.220 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2021 | 66 | 0.220 |
Why?
|
Carcinoma | 2 | 2016 | 215 | 0.210 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 561 | 0.200 |
Why?
|
Acid Ceramidase | 2 | 2013 | 85 | 0.200 |
Why?
|
Genes, Tumor Suppressor | 1 | 2022 | 61 | 0.200 |
Why?
|
Receptors, Estrogen | 2 | 2019 | 142 | 0.190 |
Why?
|
Neoplasm Invasiveness | 4 | 2020 | 369 | 0.190 |
Why?
|
Lysophospholipids | 2 | 2013 | 209 | 0.190 |
Why?
|
Video Recording | 2 | 2019 | 145 | 0.190 |
Why?
|
Bacteroides fragilis | 1 | 2021 | 20 | 0.190 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2021 | 87 | 0.190 |
Why?
|
Indazoles | 1 | 2020 | 12 | 0.190 |
Why?
|
Cell Cycle Proteins | 2 | 2019 | 230 | 0.190 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 1070 | 0.180 |
Why?
|
Soft Tissue Neoplasms | 1 | 2020 | 28 | 0.180 |
Why?
|
Sphingosine | 2 | 2013 | 315 | 0.180 |
Why?
|
Deoxycytidine | 1 | 2020 | 83 | 0.180 |
Why?
|
Acrylamides | 1 | 2020 | 12 | 0.180 |
Why?
|
Aniline Compounds | 1 | 2020 | 52 | 0.180 |
Why?
|
Immunotherapy | 2 | 2020 | 215 | 0.170 |
Why?
|
Sulfonamides | 1 | 2020 | 141 | 0.170 |
Why?
|
Mycosis Fungoides | 1 | 2019 | 16 | 0.170 |
Why?
|
Hematologic Tests | 1 | 2019 | 24 | 0.170 |
Why?
|
Pyrimidines | 1 | 2020 | 178 | 0.170 |
Why?
|
Quinazolines | 1 | 2019 | 70 | 0.170 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2019 | 41 | 0.170 |
Why?
|
Temperature | 2 | 2018 | 341 | 0.170 |
Why?
|
Th17 Cells | 1 | 2020 | 116 | 0.170 |
Why?
|
Community Health Workers | 1 | 2019 | 32 | 0.170 |
Why?
|
Gastrointestinal Microbiome | 1 | 2021 | 122 | 0.160 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2016 | 135 | 0.160 |
Why?
|
Survivorship | 1 | 2019 | 20 | 0.160 |
Why?
|
Psychology | 1 | 2018 | 36 | 0.160 |
Why?
|
Insurance Coverage | 1 | 2019 | 99 | 0.160 |
Why?
|
Graft vs Host Disease | 1 | 2021 | 163 | 0.160 |
Why?
|
Algorithms | 2 | 2022 | 1196 | 0.160 |
Why?
|
Pyrazoles | 1 | 2019 | 190 | 0.160 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2020 | 266 | 0.160 |
Why?
|
Colonoscopy | 1 | 2019 | 156 | 0.160 |
Why?
|
Neoplasm Staging | 3 | 2021 | 800 | 0.160 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2021 | 245 | 0.160 |
Why?
|
Immunoglobulin Km Allotypes | 1 | 2018 | 34 | 0.150 |
Why?
|
Piperazines | 1 | 2019 | 206 | 0.150 |
Why?
|
Mouth | 1 | 2018 | 64 | 0.150 |
Why?
|
Circadian Clocks | 1 | 2017 | 1 | 0.150 |
Why?
|
Blood-Brain Barrier | 1 | 2018 | 99 | 0.150 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 468 | 0.150 |
Why?
|
Barium Sulfate | 1 | 2018 | 66 | 0.150 |
Why?
|
ErbB Receptors | 1 | 2019 | 239 | 0.150 |
Why?
|
Papillomaviridae | 1 | 2018 | 104 | 0.150 |
Why?
|
Phosphoproteins | 1 | 2019 | 202 | 0.150 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2019 | 214 | 0.150 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 149 | 0.150 |
Why?
|
Glycation End Products, Advanced | 1 | 2018 | 125 | 0.150 |
Why?
|
Inpatients | 1 | 2019 | 208 | 0.150 |
Why?
|
Osteosarcoma | 1 | 2017 | 35 | 0.150 |
Why?
|
eIF-2 Kinase | 1 | 2017 | 49 | 0.150 |
Why?
|
Immunoglobulin Gm Allotypes | 1 | 2018 | 103 | 0.150 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2018 | 94 | 0.150 |
Why?
|
Proto-Oncogene Proteins | 1 | 2019 | 411 | 0.150 |
Why?
|
Receptors, IgG | 1 | 2018 | 94 | 0.150 |
Why?
|
Doxorubicin | 1 | 2018 | 231 | 0.150 |
Why?
|
Bone Neoplasms | 1 | 2017 | 100 | 0.140 |
Why?
|
Young Adult | 8 | 2020 | 5717 | 0.140 |
Why?
|
Carcinoma, Basal Cell | 1 | 2017 | 40 | 0.140 |
Why?
|
Plethysmography | 1 | 2016 | 17 | 0.140 |
Why?
|
Hyperthermia, Induced | 1 | 2017 | 53 | 0.140 |
Why?
|
Health Education | 1 | 2019 | 279 | 0.140 |
Why?
|
Lung Volume Measurements | 1 | 2016 | 19 | 0.140 |
Why?
|
Esophagus | 1 | 2018 | 303 | 0.140 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 62 | 0.140 |
Why?
|
Prostatic Neoplasms | 2 | 2013 | 778 | 0.140 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 46 | 0.140 |
Why?
|
Life Style | 1 | 2018 | 338 | 0.140 |
Why?
|
Keratinocytes | 1 | 2016 | 68 | 0.140 |
Why?
|
Cohort Studies | 6 | 2021 | 2358 | 0.140 |
Why?
|
Motivational Interviewing | 1 | 2016 | 40 | 0.130 |
Why?
|
Psychotherapy, Group | 1 | 2016 | 55 | 0.130 |
Why?
|
Electromyography | 1 | 2016 | 184 | 0.130 |
Why?
|
Genotype | 1 | 2018 | 786 | 0.130 |
Why?
|
Veterans Health | 1 | 2016 | 62 | 0.130 |
Why?
|
Survival Analysis | 4 | 2021 | 714 | 0.130 |
Why?
|
Melanoma, Experimental | 1 | 2016 | 95 | 0.130 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2016 | 79 | 0.130 |
Why?
|
Fluoroquinolones | 1 | 2016 | 49 | 0.130 |
Why?
|
Interpersonal Relations | 1 | 2017 | 209 | 0.130 |
Why?
|
Immunotherapy, Adoptive | 1 | 2016 | 132 | 0.130 |
Why?
|
Prostate-Specific Antigen | 1 | 2016 | 138 | 0.130 |
Why?
|
Evaluation Studies as Topic | 1 | 2015 | 219 | 0.120 |
Why?
|
Urinary Bladder | 2 | 2012 | 108 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 231 | 0.120 |
Why?
|
Physicians | 2 | 2015 | 324 | 0.120 |
Why?
|
Animals | 11 | 2021 | 20881 | 0.120 |
Why?
|
Esophagectomy | 1 | 2014 | 26 | 0.120 |
Why?
|
Health Status | 1 | 2017 | 429 | 0.120 |
Why?
|
Models, Theoretical | 1 | 2017 | 384 | 0.120 |
Why?
|
Transforming Growth Factor beta | 1 | 2017 | 384 | 0.120 |
Why?
|
Social Support | 1 | 2017 | 423 | 0.120 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 170 | 0.120 |
Why?
|
Mice | 7 | 2021 | 8474 | 0.120 |
Why?
|
Membrane Proteins | 1 | 2018 | 617 | 0.110 |
Why?
|
Health Services Research | 1 | 2015 | 209 | 0.110 |
Why?
|
Radiation Tolerance | 1 | 2013 | 30 | 0.110 |
Why?
|
Hospitalization | 1 | 2019 | 978 | 0.110 |
Why?
|
Hodgkin Disease | 1 | 2013 | 27 | 0.110 |
Why?
|
Ultrasonography, Mammary | 1 | 2013 | 39 | 0.110 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2013 | 35 | 0.110 |
Why?
|
Qualitative Research | 1 | 2015 | 369 | 0.110 |
Why?
|
Breast Diseases | 1 | 2013 | 40 | 0.110 |
Why?
|
Sphingolipids | 2 | 2013 | 337 | 0.110 |
Why?
|
Esophageal Neoplasms | 1 | 2014 | 150 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2013 | 36 | 0.110 |
Why?
|
Propanolamines | 1 | 2013 | 70 | 0.110 |
Why?
|
Colonic Neoplasms | 1 | 2015 | 299 | 0.110 |
Why?
|
Amides | 1 | 2013 | 86 | 0.110 |
Why?
|
Cystitis | 1 | 2012 | 18 | 0.110 |
Why?
|
MicroRNAs | 1 | 2017 | 447 | 0.110 |
Why?
|
Simvastatin | 1 | 2012 | 34 | 0.110 |
Why?
|
Urodynamics | 1 | 2012 | 43 | 0.110 |
Why?
|
Melanoma | 1 | 2016 | 335 | 0.110 |
Why?
|
Risk Factors | 6 | 2018 | 5731 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2012 | 57 | 0.100 |
Why?
|
Phosphorylation | 3 | 2020 | 1200 | 0.100 |
Why?
|
Cyclophosphamide | 1 | 2012 | 129 | 0.100 |
Why?
|
Organs at Risk | 1 | 2012 | 9 | 0.100 |
Why?
|
Tissue Expansion Devices | 1 | 2011 | 2 | 0.100 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2012 | 53 | 0.100 |
Why?
|
Cathepsin B | 1 | 2012 | 33 | 0.100 |
Why?
|
Rectum | 1 | 2012 | 62 | 0.100 |
Why?
|
Proto-Oncogene Protein c-ets-1 | 1 | 2012 | 65 | 0.100 |
Why?
|
Sarcoma | 1 | 2012 | 70 | 0.100 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 442 | 0.100 |
Why?
|
Prospective Studies | 5 | 2019 | 3705 | 0.100 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 432 | 0.100 |
Why?
|
Brachytherapy | 1 | 2012 | 79 | 0.100 |
Why?
|
Mammaplasty | 1 | 2011 | 41 | 0.100 |
Why?
|
Mice, Inbred C57BL | 4 | 2021 | 2791 | 0.100 |
Why?
|
Endometrial Neoplasms | 1 | 2012 | 69 | 0.100 |
Why?
|
Adenocarcinoma | 1 | 2014 | 475 | 0.100 |
Why?
|
Delivery of Health Care | 1 | 2015 | 445 | 0.100 |
Why?
|
Cell Movement | 3 | 2020 | 630 | 0.090 |
Why?
|
Research Design | 1 | 2015 | 729 | 0.090 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 212 | 0.090 |
Why?
|
Postoperative Complications | 1 | 2018 | 1615 | 0.090 |
Why?
|
Smoking | 1 | 2018 | 1452 | 0.090 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 951 | 0.090 |
Why?
|
Apoptosis | 1 | 2016 | 1641 | 0.090 |
Why?
|
Biomarkers, Tumor | 1 | 2013 | 508 | 0.080 |
Why?
|
Ceramides | 1 | 2013 | 578 | 0.080 |
Why?
|
Treatment Outcome | 5 | 2021 | 7029 | 0.080 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 1026 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 2 | 2016 | 2324 | 0.080 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 226 | 0.080 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 511 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2018 | 1553 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2016 | 1034 | 0.070 |
Why?
|
Pilot Projects | 3 | 2016 | 1342 | 0.070 |
Why?
|
United States | 5 | 2019 | 7367 | 0.070 |
Why?
|
Heterografts | 2 | 2017 | 70 | 0.070 |
Why?
|
Lung | 1 | 2011 | 849 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2021 | 597 | 0.070 |
Why?
|
Signal Transduction | 3 | 2022 | 2689 | 0.070 |
Why?
|
Adolescent | 5 | 2018 | 8912 | 0.070 |
Why?
|
Disease-Free Survival | 2 | 2019 | 349 | 0.070 |
Why?
|
Drug Delivery Systems | 2 | 2018 | 236 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 304 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 536 | 0.060 |
Why?
|
Cell Proliferation | 2 | 2020 | 1174 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2016 | 3259 | 0.060 |
Why?
|
Nanoparticles | 2 | 2018 | 254 | 0.060 |
Why?
|
Mice, Transgenic | 2 | 2017 | 1033 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2018 | 1054 | 0.060 |
Why?
|
SEER Program | 2 | 2014 | 153 | 0.060 |
Why?
|
Aneuploidy | 1 | 2022 | 21 | 0.050 |
Why?
|
DNA Copy Number Variations | 1 | 2022 | 27 | 0.050 |
Why?
|
Depression | 2 | 2019 | 943 | 0.050 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 104 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 1465 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2018 | 2077 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2021 | 2550 | 0.050 |
Why?
|
Fecal Microbiota Transplantation | 1 | 2021 | 17 | 0.050 |
Why?
|
Isoantigens | 1 | 2021 | 26 | 0.050 |
Why?
|
Graft vs Leukemia Effect | 1 | 2021 | 33 | 0.050 |
Why?
|
Surveys and Questionnaires | 2 | 2019 | 2800 | 0.050 |
Why?
|
Mice, Inbred DBA | 1 | 2021 | 120 | 0.050 |
Why?
|
Lymphatic Metastasis | 2 | 2012 | 274 | 0.050 |
Why?
|
Allografts | 1 | 2021 | 63 | 0.050 |
Why?
|
South Carolina | 2 | 2019 | 2752 | 0.050 |
Why?
|
Promoter Regions, Genetic | 2 | 2013 | 615 | 0.050 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2020 | 15 | 0.050 |
Why?
|
Glycogen Synthase Kinase 3 beta | 1 | 2020 | 57 | 0.040 |
Why?
|
A549 Cells | 1 | 2020 | 50 | 0.040 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2020 | 35 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2020 | 260 | 0.040 |
Why?
|
Proteolysis | 1 | 2020 | 97 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2021 | 532 | 0.040 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 108 | 0.040 |
Why?
|
Tumor Burden | 1 | 2019 | 132 | 0.040 |
Why?
|
Everolimus | 1 | 2019 | 26 | 0.040 |
Why?
|
Thiophenes | 1 | 2019 | 76 | 0.040 |
Why?
|
Cell Cycle Checkpoints | 1 | 2019 | 37 | 0.040 |
Why?
|
Tumor Cells, Cultured | 1 | 2021 | 852 | 0.040 |
Why?
|
Gene Amplification | 1 | 2019 | 71 | 0.040 |
Why?
|
Child | 3 | 2016 | 6405 | 0.040 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2019 | 54 | 0.040 |
Why?
|
Drug Synergism | 1 | 2019 | 260 | 0.040 |
Why?
|
MCF-7 Cells | 1 | 2019 | 80 | 0.040 |
Why?
|
Respiratory Aspiration | 1 | 2019 | 13 | 0.040 |
Why?
|
Healthy Volunteers | 1 | 2019 | 78 | 0.040 |
Why?
|
Benzimidazoles | 1 | 2019 | 128 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2020 | 330 | 0.040 |
Why?
|
Gene Knockdown Techniques | 1 | 2019 | 196 | 0.040 |
Why?
|
Neoplasm Grading | 1 | 2018 | 111 | 0.040 |
Why?
|
Proof of Concept Study | 1 | 2018 | 38 | 0.040 |
Why?
|
Viscosity | 1 | 2018 | 72 | 0.040 |
Why?
|
Tamoxifen | 1 | 2018 | 62 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 306 | 0.040 |
Why?
|
Enzyme Activation | 1 | 2020 | 791 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 199 | 0.040 |
Why?
|
Brazil | 1 | 2018 | 48 | 0.040 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2019 | 135 | 0.040 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 118 | 0.040 |
Why?
|
Epistasis, Genetic | 1 | 2018 | 32 | 0.040 |
Why?
|
Biological Transport | 1 | 2018 | 210 | 0.040 |
Why?
|
ARNTL Transcription Factors | 1 | 2017 | 6 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2020 | 331 | 0.040 |
Why?
|
Light Signal Transduction | 1 | 2017 | 6 | 0.040 |
Why?
|
Insurance, Health | 1 | 2019 | 201 | 0.040 |
Why?
|
Photoperiod | 1 | 2017 | 11 | 0.040 |
Why?
|
Antibody Formation | 1 | 2018 | 93 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2019 | 235 | 0.040 |
Why?
|
CLOCK Proteins | 1 | 2017 | 7 | 0.040 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2018 | 99 | 0.040 |
Why?
|
Microsurgery | 1 | 2018 | 46 | 0.040 |
Why?
|
Dogs | 1 | 2018 | 490 | 0.040 |
Why?
|
Unfolded Protein Response | 1 | 2017 | 70 | 0.040 |
Why?
|
Heating | 1 | 2017 | 13 | 0.040 |
Why?
|
Self Efficacy | 1 | 2018 | 199 | 0.040 |
Why?
|
Transfection | 1 | 2019 | 782 | 0.040 |
Why?
|
Physical Stimulation | 1 | 2017 | 67 | 0.040 |
Why?
|
Food | 1 | 2017 | 52 | 0.040 |
Why?
|
Precision Medicine | 1 | 2018 | 111 | 0.040 |
Why?
|
Osteoblasts | 1 | 2017 | 99 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2017 | 282 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2018 | 301 | 0.040 |
Why?
|
L-Selectin | 1 | 2016 | 28 | 0.040 |
Why?
|
Emotions | 1 | 2018 | 244 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2017 | 122 | 0.040 |
Why?
|
Area Under Curve | 1 | 2017 | 238 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2014 | 7277 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2017 | 231 | 0.030 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2016 | 30 | 0.030 |
Why?
|
Recurrence | 1 | 2019 | 948 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2018 | 652 | 0.030 |
Why?
|
Diagnosis, Dual (Psychiatry) | 1 | 2016 | 151 | 0.030 |
Why?
|
Prostatitis | 1 | 2016 | 10 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2016 | 100 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2019 | 447 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 434 | 0.030 |
Why?
|
RNA Interference | 1 | 2017 | 266 | 0.030 |
Why?
|
Necrosis | 1 | 2016 | 239 | 0.030 |
Why?
|
Cytokines | 1 | 2020 | 866 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2017 | 329 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2018 | 481 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2016 | 241 | 0.030 |
Why?
|
Swine | 1 | 2017 | 672 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 955 | 0.030 |
Why?
|
Phenotype | 1 | 2018 | 947 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2016 | 489 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 710 | 0.030 |
Why?
|
Sex Factors | 1 | 2019 | 1266 | 0.030 |
Why?
|
Registries | 1 | 2018 | 733 | 0.030 |
Why?
|
Medicine | 1 | 2015 | 52 | 0.030 |
Why?
|
Cell Survival | 1 | 2017 | 901 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2017 | 1083 | 0.030 |
Why?
|
Blotting, Western | 1 | 2017 | 954 | 0.030 |
Why?
|
Information Dissemination | 1 | 2015 | 113 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 2279 | 0.030 |
Why?
|
Prognosis | 1 | 2019 | 2093 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 125 | 0.030 |
Why?
|
Injections, Intraperitoneal | 1 | 2013 | 89 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2013 | 71 | 0.030 |
Why?
|
Transcription Factor AP-1 | 1 | 2013 | 61 | 0.030 |
Why?
|
Computer Simulation | 1 | 2017 | 706 | 0.030 |
Why?
|
Enzyme Induction | 1 | 2013 | 119 | 0.030 |
Why?
|
Maryland | 1 | 2013 | 77 | 0.030 |
Why?
|
Disease Progression | 1 | 2017 | 1038 | 0.030 |
Why?
|
Health Surveys | 1 | 2015 | 489 | 0.030 |
Why?
|
Communication | 1 | 2015 | 329 | 0.030 |
Why?
|
Biomarkers | 1 | 2018 | 1593 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2018 | 1851 | 0.030 |
Why?
|
Mice, Nude | 1 | 2013 | 294 | 0.030 |
Why?
|
Urination | 1 | 2012 | 19 | 0.030 |
Why?
|
Aging | 1 | 2019 | 911 | 0.030 |
Why?
|
Urine | 1 | 2012 | 47 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2013 | 226 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2015 | 287 | 0.030 |
Why?
|
Sarcoma, Clear Cell | 1 | 2012 | 8 | 0.030 |
Why?
|
Sarcoma, Synovial | 1 | 2012 | 11 | 0.030 |
Why?
|
Psychometrics | 1 | 2015 | 514 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2012 | 63 | 0.030 |
Why?
|
Rhabdomyosarcoma | 1 | 2012 | 36 | 0.030 |
Why?
|
Lymphatic Irradiation | 1 | 2011 | 3 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 792 | 0.030 |
Why?
|
Fiducial Markers | 1 | 2012 | 10 | 0.030 |
Why?
|
Pressure | 1 | 2012 | 252 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2016 | 1692 | 0.030 |
Why?
|
Muscle Contraction | 1 | 2012 | 210 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2012 | 124 | 0.020 |
Why?
|
Anxiety | 1 | 2015 | 422 | 0.020 |
Why?
|
Markov Chains | 1 | 2012 | 133 | 0.020 |
Why?
|
Mastectomy | 1 | 2011 | 57 | 0.020 |
Why?
|
Mental Disorders | 1 | 2017 | 659 | 0.020 |
Why?
|
Cetuximab | 1 | 2011 | 19 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2014 | 1046 | 0.020 |
Why?
|
Postoperative Care | 1 | 2012 | 163 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 242 | 0.020 |
Why?
|
Gene Expression | 1 | 2013 | 770 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2011 | 191 | 0.020 |
Why?
|
Protein Binding | 1 | 2013 | 1027 | 0.020 |
Why?
|
Cell Membrane | 1 | 2012 | 525 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 931 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2011 | 160 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2012 | 307 | 0.020 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2011 | 151 | 0.020 |
Why?
|
Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
Endosonography | 1 | 2011 | 177 | 0.020 |
Why?
|
Up-Regulation | 1 | 2012 | 682 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 767 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2011 | 419 | 0.020 |
Why?
|
Incidence | 1 | 2013 | 1603 | 0.020 |
Why?
|
Odds Ratio | 1 | 2011 | 880 | 0.020 |
Why?
|
Veterans | 1 | 2016 | 904 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2011 | 1174 | 0.020 |
Why?
|
Brain | 1 | 2018 | 2176 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2012 | 2083 | 0.020 |
Why?
|
Logistic Models | 1 | 2011 | 1420 | 0.020 |
Why?
|
Infant | 1 | 2013 | 2891 | 0.020 |
Why?
|
Child, Preschool | 1 | 2013 | 3187 | 0.020 |
Why?
|
Rats | 1 | 2012 | 5300 | 0.010 |
Why?
|